Dr Suchitra Sundaram reflects on time limited venetoclax combinations, next generation non covalent BTK inhibitors, and novel ...

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, introduce themselves and give an overview of chronic lymphocytic leukemia (CLL), highlighting symptoms and patient presentation. Dr ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that causes your bone marrow to make too many of a type of white blood cells called lymphocytes. Unlike other types of leukemia, it’s a ...

Longitudinal data reveal consistent initial responsiveness to targeted agents but limited durability once patients cycle through both BTKi and BCL2i classes.

What Is Chronic Lymphocytic Leukemia? Chronic lymphocytic leukemia (CLL) is a cancer that affects a type of white blood cell called a "lymphocyte." Lymphocytes help your body fight infection. They're ...

Sequential BCL2 inhibitor therapy shows initial responses but lacks durability, especially in patients exposed to both BTKi ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

Join Dr Krish Patel and discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and ...

Jaypirca showed superior PFS and lower discontinuation rates compared to standard treatments in CLL/SLL patients. Jaypirca reduced the risk of progression or death by 46% to 52% and had a favorable ...

The CLL17 trial showed noninferiority of fixed-duration regimens compared to continuous BTK inhibitor therapy, highlighting ...

The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...

Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...